C30Global and regional estimates for subtype-specific therapeutic and prophylactic HIV-1 vaccinesE-posterVaccines
C31HIV-1 Env markers of prevention efficacy in HVTN 704/HPTN 085, the Antibody-Mediated Prevention (AMP) trial of broadly neutralizing antibody (bnAb) VRC01 in the Americas and Europe: genotypic sieve analysisE-posterBroadly neutralizing antibodies
C32Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH studyOral abstract session with live Q&ANovel delivery systems (e.g., rings, implants, transdermal systems)
C32Three approaches to forecasting potential numbers of dapivirine ring users for HIV prevention among women in sub-Saharan AfricaE-posterNovel delivery systems (e.g., rings, implants, transdermal systems)
C32Discreetness and pain avoidance as central drivers of preferred characteristics in an HIV prevention implant among women in Zimbabwe and South AfricaE-posterNovel delivery systems (e.g., rings, implants, transdermal systems)
C32Next generation 3D-printed intravaginal rings for prevention of HIV and unplanned pregnancyE-posterNovel delivery systems (e.g., rings, implants, transdermal systems)
C32Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugsE-posterNovel delivery systems (e.g., rings, implants, transdermal systems)
C33The cost and intermediary cost-effectiveness of oral HIV self-test kit distribution across eleven distribution models in South AfricaOn-demand oral abstract sessionHIV self-testing
C33A successful launch of the first HIV self-testing pharmacy-based service demonstration project, Bangkok, ThailandOn-demand oral abstract sessionHIV self-testing
C33User assessment of HIV self-testing (HIVST) in Brazil: an acceptable tool with great potential for reaching key populations and maximize positivity yieldOn-demand oral abstract sessionHIV self-testing
401 - 410 of 870 items